TissueScan, Breast Cancer cDNA Array II

Snippet: >TXNIP expression using qPCR in 96 clinical samples across all stages of breast cancer, namely 5 normal epithelial, 23 stage I, 30 stage II, 29 stage III, and 9 stage IV metastatic biopsies (Origene, BCRT102, BCRT103), from which 90 samples yielded sufficient amount of cDNA. HPRT1 was used as an endogenous control and relative TXNIP expression levels were mea

Snippet: measured TXNIP expression using qPCR in 96 clinical samples across all stages of breast cancer, namely 5 normal epithelial, 23 stage I, 30 stage II, 29 stage III, and 9 stage IV metastatic biopsies (Origene, BCRT102, BCRT103), from which 90 samples yielded sufficient amount of cDNA. HPRT was used as an endogenous control and relative TXNIP expression levels were measured using the primers listed

Snippet: The human cancer survey RT-qPCR gene expression panels were from Origene (catalog number: BCRT102). TP-064 was purchased from Tocris (catalog number: 6008)

Snippet: 1b, c). As mRNA expression data were not available for these cohorts, INPP4B mRNA expression was examined using Tissue Scan Breast Cancer cDNA arrays I-IV (OriGene) of 130 primary human breast cancers and 16 normal breast tissues (Fig. 1c);Breast cancer cDNA arrays (176 breast cancers and 16 tumor adjacent normal breast tissues) were purchased from OriGene (BCRT101, BCRT102, BCRT103, and BCRT104)

Snippet: breast tissue samples. Briefly, TissueScan Cancer Survey Tissue qPCR panels BCRT101, BCRT102, BCRT103 and BCRT104 were arrayed onto a single 384‑well reaction plate by OriGene Technologies, Inc. Data are expressed

Snippet: All cell culture materials and classical chemotherapeutic drugs were from Sigma-Aldrich Ltd (Gillingham, UK). TissueScan qPCR Breast Cancer Disease Panels I, II, and IV (BCRT101, BCRT102, BCRT104) were purchased from OriGene Technologies